Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity.

Drug metabolism and disposition: the biological fate of chemicals - 1 Jan 2007

Wang Shou-Lin, Han Jing-Fen, He Xiao-Yang, Wang Xin-Ru, Hong Jun-Yan

Abstract excerpt

The importance of genetic variation in clinical response to various drugs is now well recognized. Identification of genetic biomarkers that can predict efficacy and toxicity of chemotherapeutic drugs in cancer patients holds great promise in treatment improvement and cost reduction. Mitomycin C (MMC) is a common anticancer drug used for the treatment of numerous types of tumors. Metabolism-mediated activation, by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to CHO Cells

Share to Cricetinae

Share to Cricetulus

Share to Mitomycin

Share to NADPH-Ferrihemoprotein Reductase

Source

Identifiers

PMID: 17062779
DOI: 10.1124/dmd.106.011056

Genes

POR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity.PMID 17062779Read ↗

Pharmacogenomics: a tool for improving cancer chemotherapy.Semantic proximity Read ↗

A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factorSemantic proximity Read ↗

Effect of genetic variation on human cytochrome p450 reductase-mediated paraquat cytotoxicity.Semantic proximity Read ↗

Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy.Semantic proximity Read ↗

Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1).Semantic proximity Read ↗

Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity.Semantic proximity Read ↗

Genetic variants contributing to daunorubicin-induced cytotoxicity.Semantic proximity Read ↗

Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs.Semantic proximity Read ↗

Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductaseSemantic proximity Read ↗

Update on pharmacogenetics in cancer chemotherapy.Semantic proximity Read ↗

Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.Semantic proximity Read ↗

V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.